Cammarata-Scalisi, FranciscoNieves, DairelisAvendano, AndreaLacruz-Rengel, Maria A.Alviarez, KarelysDavila, FrancysYavuz, Izzet2024-04-242024-04-2420180325-00751668-3501https://doi.org/10.5546/aap.2018.e303https://hdl.handle.net/11468/20228Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.esinfo:eu-repo/semantics/openAccessIsotretinoinTeratogenesisEmbryopathyArticle1162E303E307WOS:0004287438000302-s2.0-850455078842955762110.5546/aap.2018.e303Q3Q4